Skip to main content
Top
Published in: Clinical Rheumatology 5/2007

01-05-2007 | Brief Report

The significance of platelet activation in rheumatoid arthritis

Authors: Feng Wang, Nian-Song Wang, Chun-Gen Yan, Jun-Hui Li, Ling-Quan Tang

Published in: Clinical Rheumatology | Issue 5/2007

Login to get access

Abstract

We evaluated the significance of platelet activation in patients with rheumatoid arthritis (RA). The expression of CD62P and CD63 by platelets was determined using flow cytometry in 18 active RA patients, 10 remission RA and 15 normal controls. Meanwhile, the erythrocyte sedimentation rate (ESR) and C-reactive protein was also determined in all groups. The expression of CD62P in active RA patients (11.88 ± 2.47%) was significantly higher than that in remission RA group (2.85 ± 1.60%; P < 0.01) and control group (2.78 ± 1.04%; P < 0.01). The expression of CD63 in active RA patients (9.90 ± 3.02%) was significantly higher than that in remission RA group (4.11 ± 2.00%; P < 0.01) and control group (4.13 ± 1.85%; P < 0.01). The level of CRP (54.33 ± 23.35 mg/l) and ESR (86.06 ± 33.67 mm/h) in active RA patients was higher than that in remission RA group (2.55 ± 1.01 mg/l, 14.70 ± 4.57 mm/h; P < 0.01 for both) and normal control group (3.21 ± 2.18 mg/l, 12.25 ± 5.05 mm/h; P < 0.01 for both). There was a positive correlation between CD62P and ESR (r = 0.5224, P < 0.01) and also a positive correlation between CD62P and CRP (r = 0.7048, P < 0.01) as well as between CD63 and ESR (r = 0.4476, P < 0.05) but no correlation between CD63 and CRP. Platelet activation may be a sign of RA exacerbation.
Literature
1.
go back to reference Altman RD, Bloch DA, Bole GG Jr et al (1987) Development of clinical criteria for osteoarthritis. J Rheumatol 14(Suppl):3–6PubMed Altman RD, Bloch DA, Bole GG Jr et al (1987) Development of clinical criteria for osteoarthritis. J Rheumatol 14(Suppl):3–6PubMed
2.
go back to reference American College of Rheumatology Ad Hoc Committee on Clinical Guidelines (1996) Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 39(5):713–722CrossRef American College of Rheumatology Ad Hoc Committee on Clinical Guidelines (1996) Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 39(5):713–722CrossRef
3.
go back to reference American College of Rheumatology Ad Hoc Committee on Clinical Guidelines (2002) Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 46(2):328–346CrossRef American College of Rheumatology Ad Hoc Committee on Clinical Guidelines (2002) Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 46(2):328–346CrossRef
4.
go back to reference Bathon JM, Martin RW, Fleischmann RM et al (2000) A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343(22):1586–1593PubMedCrossRef Bathon JM, Martin RW, Fleischmann RM et al (2000) A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343(22):1586–1593PubMedCrossRef
5.
go back to reference Boers M, Verhoeven AC, Markusse HM et al (1997) Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350(9074):309–318PubMedCrossRef Boers M, Verhoeven AC, Markusse HM et al (1997) Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 350(9074):309–318PubMedCrossRef
6.
go back to reference Breedveld FC, Dayer JM (2000) Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 59(11):841–849PubMedCrossRef Breedveld FC, Dayer JM (2000) Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 59(11):841–849PubMedCrossRef
7.
go back to reference Bresnihan B, Alvaro-Gracia JM, Cobby M et al (1998) Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 41(12):2196–2204PubMedCrossRef Bresnihan B, Alvaro-Gracia JM, Cobby M et al (1998) Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 41(12):2196–2204PubMedCrossRef
8.
go back to reference Conn DL (2001) Resolved. Low-dose prednisone is indicated as a standard treatment in patients with rheumatoid arthritis. Arthritis Rheum 45(5):462–467PubMedCrossRef Conn DL (2001) Resolved. Low-dose prednisone is indicated as a standard treatment in patients with rheumatoid arthritis. Arthritis Rheum 45(5):462–467PubMedCrossRef
9.
go back to reference Jiang Y, Genant HK, Watt I et al (2000) A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 43(5):1001–1009PubMedCrossRef Jiang Y, Genant HK, Watt I et al (2000) A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 43(5):1001–1009PubMedCrossRef
10.
11.
go back to reference Pendl GG, Robert C, Steinert M et al (2002) Immature mouse dendritic cells enter inflamed tissue, a process that requires E- and P-selectin, but not P-selectin glycoprotein ligand 1. Blood 99(3):946–956PubMedCrossRef Pendl GG, Robert C, Steinert M et al (2002) Immature mouse dendritic cells enter inflamed tissue, a process that requires E- and P-selectin, but not P-selectin glycoprotein ligand 1. Blood 99(3):946–956PubMedCrossRef
12.
go back to reference Genbacev OD, Prakobphol A, Foulk RA et al (2003) Trophoblast L-selectin-mediated adhesion at the maternal-fetal interface. Science 299(5605):405–408PubMedCrossRef Genbacev OD, Prakobphol A, Foulk RA et al (2003) Trophoblast L-selectin-mediated adhesion at the maternal-fetal interface. Science 299(5605):405–408PubMedCrossRef
13.
go back to reference Ma YQ, Geng JG (2000) Heparan sulfate-like proteoglycans mediate adhesion of human malignant melanoma A375 cells to P-selectin under flow. J Immunol 165(1):558–565PubMed Ma YQ, Geng JG (2000) Heparan sulfate-like proteoglycans mediate adhesion of human malignant melanoma A375 cells to P-selectin under flow. J Immunol 165(1):558–565PubMed
14.
go back to reference Frenette PS, Mayadas TN, Rayburn H et al (1996) Susceptibility to infection and altered hematopoiesis in mice deficient in both P- and E-selectins. Cell 84(4):563–574PubMedCrossRef Frenette PS, Mayadas TN, Rayburn H et al (1996) Susceptibility to infection and altered hematopoiesis in mice deficient in both P- and E-selectins. Cell 84(4):563–574PubMedCrossRef
15.
go back to reference Frenette PS, Wagner DD (1997) Insights into selectin function from knockout mice. Thromb Haemost 78(1):60–64PubMed Frenette PS, Wagner DD (1997) Insights into selectin function from knockout mice. Thromb Haemost 78(1):60–64PubMed
16.
go back to reference Hartwell DW, Wagner DD (1999) New discoveries with mice mutant in endothelial and platelet selectins. Thromb Haemost 82(2):850–857PubMed Hartwell DW, Wagner DD (1999) New discoveries with mice mutant in endothelial and platelet selectins. Thromb Haemost 82(2):850–857PubMed
Metadata
Title
The significance of platelet activation in rheumatoid arthritis
Authors
Feng Wang
Nian-Song Wang
Chun-Gen Yan
Jun-Hui Li
Ling-Quan Tang
Publication date
01-05-2007
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 5/2007
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-007-0550-0

Other articles of this Issue 5/2007

Clinical Rheumatology 5/2007 Go to the issue